Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rapid Micro Biosystems, Inc. (NASDAQ: RPID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an emerging growth company listed on Nasdaq, Rapid Micro Biosystems reports material events, financial results, and financing arrangements through forms such as Form 8-K, as well as its periodic reports on Forms 10-Q and 10-K.
Recent 8-K filings referenced in company communications include results of operations and financial condition for specific quarters and details of a Loan and Security Agreement with Trinity Capital Inc. These filings describe a five-year, $45 million term loan facility, the structure of tranches, interest terms, security interests in company assets, warrant issuance to lenders, and customary covenants and events of default. Other 8-K items incorporate press releases announcing quarterly financial results, including product revenue, service revenue, recurring revenue, and system placement and validation activity.
Through this page, users can review quarterly reports (Form 10-Q), which typically contain more detailed financial statements, segment information, and risk factor updates, and annual reports (Form 10-K), which provide a comprehensive overview of the company’s business, including its Growth Direct system, microbial quality control focus, and role in pharmaceutical manufacturing quality control. Filings related to debt facilities, warrant issuance, and other securities transactions are also accessible.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as revenue composition, recurring revenue trends, capital structure changes, covenant terms, and material events. Users interested in Rapid Micro Biosystems’ regulatory history, financial condition, and obligations under its loan facility can use this page to follow new filings as they are made available through EDGAR.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes reported an automatic sale of Class A common stock to cover taxes tied to restricted stock unit vesting. He sold 17,254 shares at an average price of
RAPID MICRO BIOSYSTEMS, INC. president and CEO Robert G. Spignesi Jr. reported a sale of 38,327 shares of Class A common stock on February 19, 2026 at an average price of $3.8853 per share. A footnote explains this was an automatic sale to cover tax obligations arising from the vesting of restricted stock units, rather than a discretionary open-market trade. After this transaction, he still holds 1,187,770 shares of the company’s Class A common stock directly.
RPID reported a proposed sale of 5,403 shares of Class A common stock under Rule 144.
The notice shows the shares are associated with a Restricted Stock Vesting event dated
Sean M. Wirtjes reports a proposed sale of Class A shares. The notice lists 17,254 Class A shares to be sold in connection with restricted stock vesting dated
RPID filed a Form 144 reporting a proposed sale of Class A shares by an affiliate. The filing lists 38,327 Class A shares to be sold with an aggregate amount of $148,911.89, dated 02/18/2026. The filing also shows 12,840 Class A shares sold during the past three months for $48,569.87.
Rapid Micro Biosystems chief operating officer John J. Addington Wilson received new equity awards as part of his compensation. He was granted 74,000 shares of Class A common stock, reported at a price of $0 and bringing his direct holdings to 331,768 shares. These shares represent restricted stock units that vest over three years, with 33.4% vesting on the first anniversary of February 11, 2026 and 33.3% on each of the next two anniversaries, conditioned on continued service. He was also granted a stock option for 147,000 shares of Class A common stock with a $4.20 exercise price, expiring on February 10, 2036. The option vests in 48 equal monthly installments starting March 11, 2026, leaving him with 147,000 options beneficially owned after the transaction.
Rapid Micro Biosystems, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean M. Wirtjes. On February 11, 2026, he received 97,000 Class A common stock restricted stock units, awarded at $0 per share, increasing his directly held Class A shares to 580,928 after the grant.
He was also granted a stock option for 193,000 shares of Class A common stock with an exercise price of $4.2 per share. The RSUs vest in three annual installments starting on the first anniversary of the grant date, while the option vests in 48 equal monthly installments beginning March 11, 2026, contingent on continued service.
Rapid Micro Biosystems, Inc. President and CEO Robert G. Spignesi Jr., who is also a director, reported equity compensation awards. He received 264,000 shares of Class A common stock on February 11, 2026 as a grant of restricted stock units that vest over three years.
The RSUs vest in three annual installments, with 33.4% vesting on the first anniversary of the February 11, 2026 grant date and 33.3% vesting on each of the next two anniversaries, subject to continued service. He was also granted a stock option covering 528,000 shares at an exercise price of $4.20 per share, vesting in 48 equal monthly installments starting March 11, 2026 and expiring February 10, 2036. Following these awards, he directly beneficially owns 1,226,097 shares of Class A common stock and 528,000 stock options.
Rapid Micro Biosystems, Inc. (RPID) received an updated ownership disclosure showing that investment entities affiliated with Endeavour Medtech collectively report beneficial ownership of 2,257,099 shares of Class A common stock, representing 5.7% of the class, based on 39,823,026 shares outstanding as of October 31, 2025.
The shares are held of record by Endeavour Medtech Growth II LP (2,217,190 shares) and Endeavour Medtech Growth II Parallel LP (39,909 shares), with Endeavour Medtech II GP Limited as general partner. The reporting group certifies the holdings are not for the purpose of changing or influencing control of the company.
Rapid Micro Biosystems chief operating officer John J. Addington Wilson reported a sale of 4,610 shares of Class A common stock on February 9, 2026. The shares were sold at $3.7827 per share in an automatic transaction to cover tax obligations from vesting restricted stock units.
Following this transaction, Wilson directly beneficially owned 257,768 Class A shares. This total includes 29,904 shares that were acquired through the company’s employee stock purchase plan on March 14, 2025.